Based on the above evidence and our meta-analysis results, we think that the therapeutic response of IDH inhibitor monotherapy (CR 23%, ORR 42%, 2-year OS 28%) and combination therapy (CR 57%, ORR 76%, 2-year OS 55%, 2-year EFS 31%) in patients with newly diagnosed IDH-mutated AML is not significantly better than other therapies, but IDH inhibitor combination therapy shows comparable survival results. The gene discussed is IDH1; the disease is acute myeloid leukemia.